Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma.

Abstract

PURPOSE:

Thiotepa is used in high-dose chemotherapy (HDT) before autologous hematopoietic stem cell transplantation (HSCT) to treat solid tumors and hematological malignancies. This Phase 1 study was conducted to establish the pharmacokinetics (PK) of thiotepa in a Japanese population.

METHODS:

HDT/HSCT was performed in pediatric patients (≥ 2 years) with solid tumors or brain tumors (thiotepa 200 mg/m2/day IV-infused over 24 h on HSCT Days - 12, - 11, - 5, and - 4 and melphalan 70 mg/m2/day IV-infused over 1 h on Days - 11, - 5, and - 4) and adult patients (≥ 16 years) with malignant lymphoma (thiotepa 200 mg/m2/day 2-h IV-infusion on HSCT Days - 4 and - 3 plus busulfan 0.8 mg/kg 2-h IV-infusion every 6 h from HSCT Days - 8 to - 5). Pharmacokinetics of thiotepa were assessed following initial dose. Safety and efficacy were also evaluated.

RESULTS:

Nine pediatric and 10 adult patients were enrolled. Mean volume of distribution (Vz) of thiotepa normalized with body surface area (BSA) was lower for pediatric patients (16.4 L/m2) compared with adult patients (26.4 L/m2) as expected due to the higher specific surface area of children. Clearance and biological half-life were similar between pediatric and adult patients. Two serious adverse events (cardiac arrest and pulmonary edema) were observed. Survival rate (Day 100 post-HSCT) was 77.8% (95% CI 36.5-93.9%) for pediatric patients and 100% for adult patients.

CONCLUSION:

Thiotepa elimination was comparable in pediatric and adult patients with cancer. Lower Vz in pediatric compared with adult patients was expected. HDT with thiotepa prior to autologous HSCT was well tolerated.

STUDY REGISTRATION:

Japic CTI-163433.

• Authors: Eisei Kondo, Takashi Ikeda, Hiroaki Goto, Momoko Nishikori, Naoko Maeda, Kimikazu Matsumoto, Hideo Kitagawa, Naoto Noda, Saori Sugimoto, Junichi Hara
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 84 Issue 4 Pg. 849-860 (10 2019) ISSN: 1432-0843 [Electronic] Germany
• PMID: 31428821 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Alkylating
• Thiotepa

Topics

• Age Factors
• Antineoplastic Agents, Alkylating (administration & dosage, adverse effects, pharmacokinetics)
• Body Surface Area
• Brain Neoplasms (drug therapy, pathology)
• Child
• Dose-Response Relationship, Drug
• Drug Monitoring (methods)
• Female
• Heart Arrest (chemically induced, diagnosis)
• Hematologic Neoplasms (drug therapy, pathology)
• Humans
• Lymphoma (drug therapy, pathology)
• Male
• Metabolic Clearance Rate
• Middle Aged
• Neoplasm Staging
• Outcome and Process Assessment, Health Care
• Pulmonary Edema (chemically induced, diagnosis)
• Thiotepa (administration & dosage, adverse effects, pharmacokinetics)